Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
DOCK4 Regulation of Rho GTPases Mediates Pulmonary Vascular Barrier Function.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: April 28, 2022
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1.
Journal: Inflammatory bowel diseases
Published: August 21, 2018
A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials.
Journal: Drug safety
Published: May 09, 2018
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Journal: Journal of Crohn's & colitis
Published: February 01, 2018
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Journal: Clinical pharmacokinetics
Published: May 20, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Journal: Journal of Crohn's & colitis
Published: March 24, 2017
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
Journal: Clinical drug investigation
Published: July 17, 2016
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Journal: Gut
Published: November 11, 2015
Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database.
Journal: Current medical research and opinion
Published: July 03, 2015
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 16, 2014
Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.
Journal: The American journal of gastroenterology
Published: July 04, 2014
Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results.
Journal: Gut
Published: April 26, 2014
Last Updated: 09/26/2026